[
  {
    "ts": null,
    "headline": "Retiring On Dividends: SCHD Vs. Covered Call ETFs",
    "summary": "Compare SCHD and covered call ETFs like JEPI for retirement income. Read about which passive income strategy best funds your retirement goals.",
    "url": "https://finnhub.io/api/news?id=7bc44d4c484196bf9999683817fa3de9c53ff6918b0f9411feb48d02865b0202",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764684031,
      "headline": "Retiring On Dividends: SCHD Vs. Covered Call ETFs",
      "id": 137664425,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2210232423/image_2210232423.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Compare SCHD and covered call ETFs like JEPI for retirement income. Read about which passive income strategy best funds your retirement goals.",
      "url": "https://finnhub.io/api/news?id=7bc44d4c484196bf9999683817fa3de9c53ff6918b0f9411feb48d02865b0202"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers",
    "summary": "AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie's blood cancer portfolio will be featured in multiple oral and poster presentations including investiga",
    "url": "https://finnhub.io/api/news?id=c4f3e6cf1b7160cff00391f39482098f1b5d65c222a754947f196bd520037818",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764681300,
      "headline": "AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers",
      "id": 137662216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie's blood cancer portfolio will be featured in multiple oral and poster presentations including investiga",
      "url": "https://finnhub.io/api/news?id=c4f3e6cf1b7160cff00391f39482098f1b5d65c222a754947f196bd520037818"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy Now and Hold For a Decade",
    "summary": "These healthcare leaders can make you money while you sleep.",
    "url": "https://finnhub.io/api/news?id=3dafbd5f4e7abb1cc3c77a6ec5d34d10d4db2be93488e29fe6294977d96c972c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764679440,
      "headline": "2 Top Dividend Stocks to Buy Now and Hold For a Decade",
      "id": 137662217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These healthcare leaders can make you money while you sleep.",
      "url": "https://finnhub.io/api/news?id=3dafbd5f4e7abb1cc3c77a6ec5d34d10d4db2be93488e29fe6294977d96c972c"
    }
  },
  {
    "ts": null,
    "headline": "XLV: The Simple Case For Overweighting U.S. Health Care",
    "summary": "Discover why XLV Health Care ETF may offer strong growth, low beta, and momentum.",
    "url": "https://finnhub.io/api/news?id=855c26666a002d7a79c5c67f7d2902ba7688f3d5dc1628720974bebf4d809052",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764676597,
      "headline": "XLV: The Simple Case For Overweighting U.S. Health Care",
      "id": 137663711,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/467786549/image_467786549.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why XLV Health Care ETF may offer strong growth, low beta, and momentum.",
      "url": "https://finnhub.io/api/news?id=855c26666a002d7a79c5c67f7d2902ba7688f3d5dc1628720974bebf4d809052"
    }
  },
  {
    "ts": null,
    "headline": "Arcutis Biotherapeutics: Behind The Big Rally",
    "summary": "Arcutis Biotherapeutics surges on strong Q3 results, Zoryve growth, and a bullish FY 2026 outlook. Click here to find out why ARQT stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=12b2848b920054e75ac18fe0cb67b57ddccbb6a1ae9cdb623675d241003a7c8a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764672784,
      "headline": "Arcutis Biotherapeutics: Behind The Big Rally",
      "id": 137663357,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Arcutis Biotherapeutics surges on strong Q3 results, Zoryve growth, and a bullish FY 2026 outlook. Click here to find out why ARQT stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=12b2848b920054e75ac18fe0cb67b57ddccbb6a1ae9cdb623675d241003a7c8a"
    }
  }
]